EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Circ‐Eif3c Carried by M2 Macrophage‐Derived Exosomes Mitigates Asthma Progression via miR‐15a‐5p/GSS/SOCS6 Axis Inhibition

Jiaying Yuan, Jiayi Zhao, Xiahui Ge, Xingxing Zhu, Li Li, Haoran Ni, Jian Fan, Yi Zhang, Yahong Sun, Yan Shang

Mediators of Inflammation · 2026-01 · 2026 (1)

DOI: 10.1155/mi/8350424 ↗
AbstractBibliografische Angaben

Abstract

Background In the study, we aimed to uncover potential therapeutic mechanisms concerning M2 macrophage‐derived exosomes in asthma. Methods Exosomes were isolated from M0Φ‐Exos and M2Φ‐Exos. An ovalbumin (OVA)‐induced asthma mouse model or lipopolysaccharide (LPS)‐induced alveolar epithelial cells (AECs) were created to unravel the therapeutic mechanisms. High‐throughput sequencing was used to search for differentially expressed circRNA. Bioinformation analysis and luciferase report analysis were used to reveal the regulationship among circ‐Eif3c, miR‐15a‐5p, glutathione synthetase (GSS), and suppressor of cytokine signaling 6 (SOCS6). Results The results showed that M2Φ‐Exos suppressed OVA‐induced inflammatory cytokine secretion and lung injury in mice. Next‐generation sequencing (NGS) showed that circ‐Eif3c was upregulated in M2Φ‐Exos. Circ‐Eif3c downregulation inhibited the therapeutic effect of M2Φ‐Exos. Bioinformation analysis confirmed that miR‐15a‐5p, GSS, and SOCS6 were the downstream targets of circ‐Eif3c, which were confirmed by luciferase report analysis. The overexpression of miR‐15a‐5p or the downregulation of GSS/SOCS6 reversed circ‐Eif3c’s protective effects on LPS‐induced AEC damage. The overexpression of circ‐Eif3c increased the therapeutic effect of M2Φ‐Exos. Conclusion In conclusion, circ‐Eif3c‐enriched M2Φ‐Exos attenuated airway remodeling by restoring the function of AECs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →